Malignancies in systemic lupus erythematosus

Autoimmunity Reviews

Volumn 9, Issue 4, 2010, Pages 195-199

  Kiss, Emese ^a   Kovacs, Laszlo ^b   Szodoray, Peter ^c  

^a NATIONAL INSTITUTE OF RHEUMATOLOGY AND PHYSIOTHERAPY   (Hungary)

^b UNIVERSITY OF SZEGED   (Hungary)

^c UNIVERSITY OF OSLO   (Norway)

Author keywords

EBV; Genetics; Lupus; Malignancy; Pathogenesis; Smoking

Indexed keywords

ACETYLSALICYLIC ACID; ANTIMALARIAL AGENT; ANTINUCLEAR ANTIBODY; CA 125 ANTIGEN; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL CONTRACEPTIVE AGENT; TUMOR MARKER;

BLADDER CANCER; BREAST CANCER; CANCER GROWTH; CANCER INCIDENCE; CANCER RISK; CLINICAL FEATURE; COLORECTAL CANCER; CYTOPENIA; FATIGUE; FEVER; FOLLOW UP; GENETIC PREDISPOSITION; HEPATOBILIARY DISEASE; HEPATOSPLENOMEGALY; HODGKIN DISEASE; HORMONE SUBSTITUTION; HUMAN; LUNG CANCER; LUNG FIBROSIS; LYMPHADENOPATHY; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUTH CANCER; NEOPLASM; NIGHT SWEAT; NONHODGKIN LYMPHOMA; NONHUMAN; OVARY CANCER; REVIEW; SEXUALLY TRANSMITTED DISEASE; SKIN CANCER; SYSTEMIC LUPUS ERYTHEMATOSUS; UTERINE CERVIX CARCINOMA; WEIGHT REDUCTION;

CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; ESTROGENS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNITY; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOMA, NON-HODGKIN; POLYMORPHISM, GENETIC; RISK FACTORS; TUMOR VIRUS INFECTIONS;

EID: 73649134013     PISSN: 15689972     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.autrev.2009.07.004     Document Type: Review

References (38)

1. Ehrenstein M.R., and Isenberg D.A. Systemic lupus erythematosus in adults-clinical features and etiopathogenesis. In: Isenberg D.A., Maddison P.J., Woo P., Glass D., and Breedveld F.C. (Eds). Oxford textbook of rheumatology. 3rd Ed. (2004), Oxford University Press, Oxford UK 819-842
2. Petri M. Systemic lupus erythematosus and related diseases: clinical features. In: Rose N.R., and Mackay I.R. (Eds). The autoimmune diseases. 4th Edition (2006), Elsevier Academic Press, London, UK 351-356
3. Nossent J., Cikes N., Kiss E., Marchesoni A., Nassonova V., Mosca M., et al. Current causes of death in systemic lupus erythematosus in Europe, 2000-2004: relation to disease activity and damage accrual. Lupus 16 5 (2007) 309-317
4. Bernatsky S., Ramsey-Goldman R., and Clarke A. Malignancy and autoimmunity. Curr Opin Rheumatol 18 2 (2006) 129-134
5. Bernatsky S., Boivin J.F., Joseph L., Manzi S., Ginzler E., Urowitz M., et al. Race/ethnicity and cancer occurrence in systemic lupus erythematosus. Arthritis Rheum 53 5 (2005) 781-784
6. Zintzaras E., Voulgarelis M., and Moutsopoulos H.M. The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med 165 20 (2005) 2337-2344
7. Váróczy L., Gergely L., Zeher M., Szegedi G., and Illés A. Malignant lymphoma-associated autoimmune diseases-a descriptive epidemiological study. Rheumatol Int 22 6 (2002) 233-237
8. Racanelli V., Prete M., Minoia C., Favoino E., and Perosa F. Rheumatic disorders as paraneoplastic syndromes. Autoimmun Rev 7 5 (2008) 352-358
9. Tincani A., Taraborelli M., and Cattaneo R. Antiphospholipid antibodies and malignancies. Autoimmun Rev (Apr 19 2009) [Electronic publication ahead of print], doi:10.1016/j.autrev.2009.04.001
10. Ekström Smedby K., Vajdic C.M., Falster M., Engels E.A., Martínez-Maza O., Turner J., et al. Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium. Blood 111 8 (2008) 4029-4038
11. Bernatsky S., Clarke A., and Ramsey-Goldman R. Malignancy and systemic lupus erythematosus. Curr Rheumatol Rep 4 4 (2002) 351-358
12. Poole B.D., Templeton A.K., Guthridge J.M., Brown E.J., Harley J.B., and James J.A. Aberrant Epstein-Barr viral infection in systemic lupus erythematosus. Autoimmun Rev 8 4 (2009) 337-342
13. Ferraccioli G., and Tolusso B. Infections, B cell receptor activation and autoimmunity: different check-point impairments lead to autoimmunity, clonal B cell expansion and fibrosis in different immunological settings. Autoimmun Rev 7 2 (2007) 109-113
14. Illes A., Varoczy L., Papp G., Wilson P.C., Alex P., Jonsson R., et al. Aspects of B-cell non-Hodgkin's lymphoma development: a transition from immune-reactivity to malignancy. Scand J Immunol 69 5 (2009) 387-400
15. Ghia P., Scielzo C., Frenquelli M., Muzio M., and Caligaris-Cappio F. From normal to clonal B cells: chronic lymphocytic leukemia (CLL) at the crossroad between neoplasia and autoimmunity. Autoimmun Rev 7 2 (2007) 127-131
16. Vidalino L., Doria A., Quarta S., Zen M., Gatta A., and Pontisso P. SERPINB3, apoptosis and autoimmunity. Autoimmun Rev (Mar 27 2009) [Electronic publication ahead of print], doi:10.1016/j.autrev.2009.03.011
17. Szodoray P., Jellestad S., Alex P., Zhou T., Wilson P.C., Centola M., et al. Programmed cell death of peripheral blood B cells determined by laser scanning cytometry in Sjögren's syndrome with a special emphasis on BAFF. J Clin Immunol 24 6 (2004) 600-611
18. Chu V.T., Enghard P., Schürer S., Steinhauser G., Rudolph B., Riemekasten G., et al. Systemic activation of the immune system induces aberrant BAFF and APRIL expression in B cells in patients with systemic lupus erythematosus. Arthritis Rheum 60 7 (2009) 2083-2093
19. Shivakumar L., and Ansell S. Targeting B-lymphocyte stimulator/B-cell activating factor and a proliferation-inducing ligand in hematologic malignancies. Clin Lymphoma Myeloma 7 2 (2006) 106-108
20. Puliaeva I., Puliaev R., and Via C.S. Therapeutic potential of CD8+ cytotoxic T lymphocytes in SLE. Autoimmun Rev 8 3 (2009) 219-223
21. Tarr T., Gyorfy B., Szekanecz E., Bhattoa H.P., Zeher M., Szegedi G., et al. Occurrence of malignancies in Hungarian patients with systemic lupus erythematosus: results from a single center. Ann N Y Acad Sci 1108 (2007) 76-82
22. Bernatsky S., Boivin J.F., Joseph L., Rajan R., Zoma A., Manzi S., et al. An international cohort study of cancer in systemic lupus erythematosus. Arthritis Rheum 52 5 (2005) 1481-1490
23. Simon Z., Tarr T., Ress Z., Gergely L., Kiss E., and Illes A. Successful rituximab-CHOP treatment of systemic lupus erythematosus associated with diffuse large B-cell non-Hodgkin lymphoma. Rheumatol Int 28 2 (2007) 179-183
24. Okada T., Takiura F., Tokushige K., Nozawa S., Kiyosawa T., Nakauchi H., et al. Major histocompatibility complex controls clonal proliferation of CD5+ B cells in H-2-congenic New Zealand mice: a model for B cell chronic lymphocytic leukemia and autoimmune disease. Eur J Immunol 21 11 (1991) 2743-2748
25. Hamano Y., Hirose S., Ida A., Abe M., Zhang D., Kodera S., et al. Susceptibility alleles for aberrant B-1 cell proliferation involved in spontaneously occurring B-cell chronic lymphocytic leukemia in a model of New Zealand white mice. Blood 92 10 (1998) 3772-3779
26. Bernatsky S., Ramsey-Goldman R., Isenberg D., Rahman A., Dooley M.A., Sibley J., et al. Hodgkin's lymphoma in systemic lupus erythematosus. Rheumatology (Oxford) 46 5 (2007) 830-832
27. Bin J., Bernatsky S., Gordon C., Boivin J.F., Ginzler E., Gladman D., et al. Lung cancer in systemic lupus erythematosus. Lung Cancer 56 3 (2007) 303-306
28. Murin S., Wiedemann H.P., and Matthay R.A. Pulmonary manifestations of systemic lupus erythematosus. Clin Chest Med 19 4 (1998) 641-665
29. Dhar J., Kmak D., Bhan R., Pishorodi L., Ager J., and Sokol R. Abnormal cervicovaginal cytology in women with lupus: a retrospective cohort study. Gynecol Oncol 82 (2001) 4-6
30. Bateman H., Yazici Y., Leff L., Peterson M., and Paget S.A. Increased cervical dysplasia in intravenous cyclophosphamide-treated patients with SLE: a preliminary study. Lupus 9 (2000) 542-544
31. Bernatsky S., Ramsey-Goldman R., Gordon C., Joseph L., Boivin J.F., Rajan R., et al. Factors associated with abnormal Pap results in systemic lupus erythematosus. Rheumatology (Oxford) 43 11 (2004) 1386-1389
32. Bjornadal L., Lofstrom B., Yin L., Lundberg I., and Ekbom A. Increased cancer incidence in a Swedish cohort of patients with systemic lupus erythematosus. Scand J Rheumatol 31 (2002) 66-71
33. Mellemkjaer L., Andersen V., Linet M.S., Gridley G., Hoover R., and Olsen J.H. Non-Hodgkin's lymphoma and other cancers among a cohort of patients with systemic lupus erythematosus. Arthritis Rheum 40 (1997) 761-768
34. Ramsey-Goldman R., Mattai S.A., Schilling E., Chiu Y.L., Alo C.J., and Howe H.L. Increased risk of malignancy in patients with systemic lupus erythematosus. J Invest Med 46 (1998) 217-222
35. Ramsey-Goldman R., and Clarke A. Double trouble: are lupus and malignancy associated?. Lupus 10 (2001) 388-391
36. Bernatsky S., Clarke A., Ramsey-Goldman R., Joseph L., Boivin J.F., Rajan R., et al. Hormonal exposures and breast cancer in a sample of women with systemic lupus erythematosus. Rheumatology (Oxford) 43 9 (2004) 1178-1181
37. Bernatsky S., Joseph L., Boivin J.F., Gordon C., Urowitz M., Gladman D., et al. The relationship between cancer and medication exposures in systemic lupus erythaematosus: a case-cohort study. Ann Rheum Dis 67 1 (2008) 74-79
38. Szekanecz E., Szucs G., Szekanecz Z., Tarr T., Antal-Szalmás P., Szamosi S., et al. Tumor-associated antigens in systemic sclerosis and systemic lupus erythematosus: associations with organ manifestations, immunolaboratory markers and disease activity indices. J Autoimmun 31 4 (2008) 372-376